Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab

INTRODUCTION: Approximately 3%–10% of asthma patients will remain uncontrolled despite maximum, optimal conventional therapy. Treatment of severe refractory asthma often involves the use of targeted biological therapy. Randomised controlled trials have shown improvements in clinical parameters with...

Descripción completa

Detalles Bibliográficos
Autores principales: Walsh, Laura J., Casey, Deborah, Vairamani, Punitha, Arnott, Fiona, Plant, Barry J., Murphy, Desmond M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Allergy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845591/
https://www.ncbi.nlm.nih.gov/pubmed/36686966
http://dx.doi.org/10.3389/falgy.2022.1052339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845591/
https://www.ncbi.nlm.nih.gov/pubmed/36686966
http://dx.doi.org/10.3389/falgy.2022.1052339

Ejemplares similares